Transchem Ltd

Transchem Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 10 April 2026. This change is primarily driven by a marked improvement in technical indicators, even as the company continues to grapple with weak financial fundamentals and valuation concerns. The stock’s recent price surge and technical momentum have prompted a reassessment, though caution remains warranted given ongoing operational losses and negative returns on capital.

Transchem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 02 March 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 06 April 2026, providing investors with the latest perspective on the company’s position.

Transchem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 2 March 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 March 2026, providing investors with the latest insights into its performance and outlook.

Transchem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 2 March 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Transchem Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 2 March 2026, reflecting a complex interplay of deteriorating financial fundamentals, cautious valuation metrics, and mixed technical signals. Despite impressive long-term returns, recent quarterly losses and weakening operational metrics have raised concerns among analysts, prompting a reassessment of the stock’s outlook.

Transchem Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by improved technical indicators despite ongoing financial challenges. The pharmaceutical and biotechnology company’s recent performance reveals a complex picture where technical momentum contrasts with deteriorating fundamentals, prompting a nuanced reassessment of its investment appeal.

Transchem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 20 February 2026, providing investors with the most up-to-date insight into the stock’s fundamentals and market performance.

Transchem Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 6 February 2026. This change reflects a nuanced shift in the company’s technical outlook despite ongoing financial challenges, with the MarketsMOJO Mojo Score adjusting to 31.0. Investors are advised to consider the detailed analysis across quality, valuation, financial trends, and technical indicators before making decisions.

Transchem Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹204.00 crores, reported net profit of ₹0.68 crores for Q2 FY26, down 31.31% quarter-on-quarter from ₹0.99 crores in Q1 FY26. The company continues to face operational challenges, with zero sales recorded for the second consecutive quarter whilst remaining almost entirely dependent on other income to sustain profitability.

Transchem Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 February 2026. This adjustment reflects a complex interplay of deteriorating financial fundamentals, cautious valuation metrics, and nuanced technical signals, despite the company’s impressive long-term stock returns. Investors are urged to carefully consider these factors amid the evolving market landscape.

Transchem Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 January 2026, providing investors with the latest insights into the company's performance and outlook.

Transchem Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 07 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Transchem Ltd has surged to a fresh 52-week and all-time high of Rs.194.25, reflecting a robust rally that has propelled the stock to new heights within the Pharmaceuticals & Biotechnology sector. This milestone underscores the stock’s strong momentum amid a broader market environment showing signs of recovery.

Transchem Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.194.25 on 5 Jan 2026, reflecting a sustained period of robust gains and outperforming broader market indices significantly.

Transchem Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week and all-time high of Rs.190.45 today, reflecting a robust rally and sustained momentum over recent trading sessions.